Advertisement
U.S. markets close in 2 hours 14 minutes
  • S&P 500

    5,252.58
    +4.09 (+0.08%)
     
  • Dow 30

    39,773.91
    +13.83 (+0.03%)
     
  • Nasdaq

    16,383.37
    -16.15 (-0.10%)
     
  • Russell 2000

    2,124.57
    +10.22 (+0.48%)
     
  • Crude Oil

    82.92
    +1.57 (+1.93%)
     
  • Gold

    2,239.90
    +27.20 (+1.23%)
     
  • Silver

    24.93
    +0.18 (+0.74%)
     
  • EUR/USD

    1.0799
    -0.0030 (-0.28%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • GBP/USD

    1.2626
    -0.0012 (-0.09%)
     
  • USD/JPY

    151.3680
    +0.1220 (+0.08%)
     
  • Bitcoin USD

    70,673.68
    +1,562.78 (+2.26%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

Novartis To In-License COVID-19 Treatment From Molecular Partners, After Encouraging Mid-Stage Data

After getting positive trial data, Novartis AG (NYSE: NVS) said it would in-license a new drug developing with Molecular Partners AG (NASDAQ: MOLN) to treat COVID-19.

  • Novartis will pay CHF 150 million to in-license ensovibep from Molecular Partners.

  • The decision comes after the two companies said they had received positive topline data from a phase 2 study for ensovibep (mp0420), an antiviral therapeutic for COVID-19.

  • Related Link: Molecular Partners' Ensovibep Shows Early Safety Profile In COVID-19.

  • The DARPin (Designed Ankyrin Repeat Protein) antiviral therapeutic candidate met the primary endpoint of viral load reduction over eight days in a study in acute COVID-19 ambulatory patients comparing single intravenous doses of ensovibep versus placebo.

  • The companies said the two secondary endpoints showed a clinically meaningful benefit compared with a placebo.

  • Novartis will first seek Emergency Use approval from the FDA.

  • The companies agreed to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies for cancer.

  • Molecular Partners expects approximately CHF 133 million cash and cash equivalents as of December 31, 2021.

  • Upon receipt of the CHF 150 million option exercise milestone from Novartis, the company now estimates its cash runway to extend well into 2025.

  • Price Action: MOLN shares are up 43.5% at $23.70, NVS stock is up 0.04% at $89.35 during the premarket session on Monday's last check.

See more from Benzinga

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement